Literature DB >> 8095201

Clearance and tissue uptake following 4-hour and 24-hour infusions of pamidronate in rats.

M Pongchaidecha1, P T Daley-Yates.   

Abstract

Bisphosphonates are clinically useful for the treatment of bone disorders; however, there is some controversy concerning the extent to which the design of the dosage regimen influences the efficacy of these drugs. The effect of different rates of infusion of [14C] pamidronate (APD; 3-amino-1-hydroxy-propylidene-1,1-bisphosphonate) (1 mg/kg infused over 4 or 24 hr) on its pharmacokinetics was investigated in rats by the measurement of tissue disposition and plasma clearance. The pharmacokinetic parameters, including total clearance, renal clearance, and nonrenal clearance, were found to be not significantly affected by the rate of infusion. The concentration of pamidronate in tibia, liver, kidney, and spleen was also unaffected by the two infusion rates. The bone (tibia) contained the highest concentration of all the tissues sampled, and the kidney accumulated the highest concentration among the soft tissues measured; this was in contrast to previous bolus administration studies where the liver and spleen contained higher concentrations than the kidney. The disposition kinetics of pamidronate were found to be essentially multiphasic, with a rapid initial half-life that gradually tails into a very long terminal phase. A terminal half-life could not be reliably estimated as it increased with time. As a consequence a model-independent approach, based on the calculation of the total, renal, and nonrenal clearance, best served to describe the disposition kinetics of pamidronate. For this unmetabolized compound the nonrenal clearance can be ascribed to tissue binding, which appears to be essentially irreversible.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8095201

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  5 in total

1.  Further hearing loss during osteoporosis treatment with etidronate.

Authors:  S Yaşil; A Cömlekçi; A Güneri
Journal:  Postgrad Med J       Date:  1998-06       Impact factor: 2.401

2.  Ototoxicity associated with intravenous bisphosphonate administration.

Authors:  I R Reid; D A Mills; D J Wattie
Journal:  Calcif Tissue Int       Date:  1995-06       Impact factor: 4.333

Review 3.  Bone as an effect compartment : models for uptake and release of drugs.

Authors:  David Stepensky; Lilach Kleinberg; Amnon Hoffman
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates.

Authors:  Kenneth C Lasseter; Arturo G Porras; Andrew Denker; Anu Santhanagopal; Anastasia Daifotis
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 5.  Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans.

Authors:  Nadia O Bamfo; Chelsea Hosey-Cojocari; Leslie Z Benet; Connie M Remsberg
Journal:  Pharm Res       Date:  2021-07-12       Impact factor: 4.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.